



(51) International Patent Classification:

C07D 401/06 (2006.01) *A61K 31/44* (2006.01)
C07D 403/06 (2006.01) *A61P 3/10* (2006.01)
C07D 413/06 (2006.01) *A61P 25/28* (2006.01)
C07D 209/52 (2006.01) *A61P 35/00* (2006.01)
A61K 31/403 (2006.01)

(21) International Application Number:

PCT/US2015/024537

(22) International Filing Date:

6 April 2015 (06.04.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/976,350 7 April 2014 (07.04.2014) US

(71) Applicant: **RESET THERAPEUTICS, INC.** [US/US];
 260 Littlefield Avenue, Suite 200, South San Francisco,
 California (US).

(72) Inventors: **BERSOT, Ross**; 9 Las Vegas Road, Orinda,
 California 94563 (US). **HUMPHRIES, Paul**; 607 More-
 land Way, Santa Clara, California 95054 (US).

(74) Agents: **ELRIFI, Ivor R.** et al.; Cooley LLP, 1299
 Pennsylvania Avenue, NW, Suite 700, Washington, Dis-
 trict of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
 earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(54) Title: CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS



(57) Abstract: The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , A , D , E , G , J , L , M , Q , a , and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.